

Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin

This article was originally published [here](#)

BAT1706 is being developed by Bio-Thera Solutions as a proposed biosimilar to Avastin. The trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients

The post [Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin](#) appeared first on [Pharmaceutical Business review](#).